trending Market Intelligence /marketintelligence/en/news-insights/trending/g1gyadu3ld_11fzqlpokrg2 content esgSubNav
In This List

VBI Vaccines to delist from Toronto Stock Exchange

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


VBI Vaccines to delist from Toronto Stock Exchange

VBI Vaccines Inc. will voluntarily delist from the Toronto Stock Exchange at the close of trading on March 23.

The Cambridge, Mass.-based company said "very limited trading activity" of its shares on the TSX no longer justifies the costs of maintaining a dual-listing. Further, delisting from the TSX will allow VBI to create a central marketplace for its shares on Nasdaq, where it will continue to trade under the symbol VBIV.

The company will continue to have a significant operational presence in Ottawa.

VBI develops vaccines for use in the fields of infectious disease and immuno-oncology.